Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 37

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 37
---
X019 Phase 1 Clinical Trial Obligations. See Note 7, “ Significant Agreements” to the Condensed Consolidated Financial Statements regarding the Collaboration Agreement with BMS for more information.

License and intellectual property revenue for the nine months ended September 30, 2025, and 2024 included $50,000 in each period, respectively, in license fees recognized under the License Agreement entered into on March 1, 2020, between the Company's wholly owned subsidiary, Prothen a Biosciences Limited, and F. Hoffmann-La Roche Ltd.

Operating Expenses

                                  Three Months Ended                                        Change                          
                                  September 30,                                                                             
                                  2025                                2024                  $                         %     
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                                    
  Research and development        $                       28,938      $         50,723      $           (21,785)      (43)  
  General and administrative                              13,238                16,760                   (3,522)      (21)  
  Restructuring costs             479                                 —                     479                       nm    
  Total operating expenses        $                       42,655      $         67,483      $           (24,828)      (37)  

                                  Nine Months Ended                                          Change                          
                                  September 30,                                                                              
                                  2025                                2024                   $                         %     
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                                     
  Research and development        $                      120,266      $         172,347      $           (52,081)      (30)  
  General and administrative                              46,746                 50,351                   (3,605)      (7)   
  Restructuring costs                                     33,088      —                                    33,088      nm    
  Total operating expenses        $                      200,100      $         222,698      $           (22,598)      (10)  

__________

n/m = not meaningful

Total opera ting expenses consist of R& D expenses, general and administrative (“ G& A”) expenses, and restructuring costs. Our operating expenses were $42.7 million and $67.5 million for the three months ended September 30, 2025 and 2024, respectively,